Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Completed Journey
Companies On The Road
Follow The Artist
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Completed Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Arranta Bio
25 Articles Available
0
2
Can't find what you're looking for? Try our
advanced search
.
CDMO Acquisition
Recipharm Acquires Arranta Bio, a CDMO Leader in Advanced Therapy Medicinal Products (ATMPs), to Expand its Biologics Offering in the U.S.
PR-M02-22-17
mRNA Vaccine Manufacturing
Presenting an Integrated Solution for mRNA Vaccine Manufacturing
PAO-01-22-R250-04
mRNA Manufacturing
Serving an Accelerated Market with mRNA Production
PAO-11-21-CL-06
Investing in mRNA Production
mRNA Manufacturing
Limiting Risk In mRNA Development and Production
PAO-11-21-CL-05
mRNA Manufacturing
Integrating a Fragmented mRNA Supply Chain
PAO-11-21-CL-04
Sale
Arranta Bio Announces Completion of Sale of Florida Site and Progress on $150M Investment Plan to Expand Development and Commercial Manufacturing Services
mRNA
Integrated Support Facilitates mRNA Product Development and Commercialization
PAO-10-21-CL-15
Live Biotherapeutic Products
Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives
PAO-09-21-CL-11
mRNA Vaccines
Arranta Bio Announces First End-to-End Manufacturing for mRNA Vaccines in its Commercial-Ready GMP Facility
PR-M09-21-05
Live Biotherapeutic Products
Design Considerations for Live Biotherapeutic Product Facilities Working with Spore-Forming Bacteria
PAO-06-21-CL-10
Live Biotherapeutic Products
Framing the Narrative on CMC Development for Microbiome Therapeutics
PAO-06-21-CL-05
Manufacturing Facility
Arranta Bio Announces Addition of 130,000 sq. ft. Boxborough, Mass., Manufacturing Facility to Supply Clinical and Commercial Microbiome Products for Clients and Closes Series B Equity Financing
PR-M03-21-002
The Road to 2021
Road to 2021 Day 3: Scotland & England
PAO-04-22-R221-30
Corporate Social Responsibility
Life Imitating Science: Arranta Bio’s Commitment to Corporate Social Responsibility and Diversity
PAP-Q4-20-CL-002
The Future of Healthcare
How Does Arranta Bio Envision the Future of the Pharma/Biopharma Industry?
PAP-Q4-20-RT2-007
Microbiome CDMO
Extensive Experience Is Crucial to Speed to the Clinic and Market for Live Biotherapeutic Products
PAP-Q3-20-CL-004
Design Logic
Experience to Solve Your Microbiome Challenges
PAP-Q3-20-NI-010
The Future of Healthcare
How Is Arranta Bio Evolving its Business Model to Meet the Future of Healthcare?
PAP-Q3-20-RT2-009
Capacity Expansion
Arranta Bio Announces Mechanical Completion of Commercial-Ready Capacity for Advanced Biologics
PR-M09-20-30
Microbiome
Selecting a Microbiome CDMO Partner for the Long Term
PAP-Q2-20-CL-008
Microbiome
Reflections on a 10-Year Journey in the Microbiome
PAP-Q1-20-CL-006
The Future of Healthcare
How is Arranta Bio Preparing to Face the Future of Healthcare?
PAP-Q1-20-R2-005
Microbiome
Supporting Commercialization of Live Biotherapeutic Products for Microbiome-Based Therapies
PAP-Q4-19-CL-009
«
0
2
»